Urea Cycle Disorders Treatment Global Market Report 2024

Description

Urea cycle disorder treatment involves managing rare genetic diseases in which the body lacks the necessary enzymes to break down ammonia, leading to its accumulation and potential toxicity. The primary goal of urea cycle disorder treatment is to reduce blood ammonia levels.

The main types of treatment for urea cycle disorders include amino acid supplements, sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, and others. Amino acid supplements contain one or more of the nine essential amino acids that the body requires but cannot produce independently. Specific types of enzyme deficiencies are addressed, such as OTC (ornithine transcarbamylase), AS (argininosuccinate synthetase) for citrullinemia, AG (arginase), AL (argininosuccinate lyase), and CPS1 (carbamoyl phosphate synthase). These treatments can be administered orally and through injections, and they are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The urea cycle disorders treatment market research report is one of a series of new reports from The Business Research Company that provides urea cycle disorders treatment market statistics, including urea cycle disorders treatment industry global market size, regional shares, competitors with a urea cycle disorders treatment market share, detailed urea cycle disorders treatment market segments, market trends and opportunities, and any further data you may need to thrive in the urea cycle disorders treatment industry. This urea cycle disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urea cycle disorders treatment market size has grown steadily in recent years. It will grow from $1.29 billion in 2023 to $1.35 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The expansion observed in the historical period can be attributed to increased awareness and education, advancements in newborn screening practices, the emergence of patient support networks, and the establishment of standard of care guidelines.

The urea cycle disorders treatment market size is expected to see steady growth in the next few years. It will grow to $1.57 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The anticipated growth in the forecast period can be attributed to advancements in enzyme replacement therapy, the expansion of newborn screening programs, heightened collaboration in research efforts, the broadening of therapeutic options, and the increasing utilization of telemedicine and remote care. Noteworthy trends expected during the forecast period include the implementation of advanced gene editing techniques, initiatives focused on awareness and advocacy, the exploration of regenerative medicine approaches, the conduct of long-term safety and efficacy studies, and the development of personalized nutritional therapies.

The increasing prevalence of urea cycle disorders is anticipated to drive the growth of the market for urea cycle disorders treatment. Urea cycle disorders are metabolic inborn disorders caused by defects in enzymes or transporter molecules crucial for the liver to eliminate ammonia from the blood. The rise in the prevalence of urea cycle disorders is primarily attributed to genetic disorders. Conditions identified as urea cycle disorders (UCD) involve the accumulation of ammonia, leading to customized treatment strategies that encompass dietary control, medication, and monitoring to manage and mitigate the adverse effects. As of April 2023, the prevalence of urea cycle disorders resulting from ornithine transcarbamylase deficiency was reported as 1 in 140,000 people according to StatPearls Publishing LLC. Additionally, in January 2021, the National Library of Medicine reported 113 new cases of urea cycle disorders per 35,000 live births in the United States. Therefore, the surge in the prevalence of urea cycle disorders is a significant driver of the urea cycle disorders treatment market's growth.

The increasing number of chronic kidney disorder cases is expected to contribute to the expansion of the urea cycle disorders treatment market. Chronic kidney disease (CKD), characterized by the gradual loss of kidney function over time, utilizes urea cycle disorder treatment to manage metabolic waste, especially elevated urea levels due to impaired kidney function. As of November 2023, an estimated 7.2 million individuals are believed to have chronic kidney disease (CKD) stages 1-5, with approximately 3.5 million people in the UK experiencing the later stages of CKD (stages 3-5), where symptoms become progressively challenging to control. Hence, the growing number of chronic kidney disorder cases is a driving force behind the urea cycle disorders treatment market's growth.

A product innovation has emerged as a notable trend, with major companies focusing on creating innovative products to strengthen their market positions. For example, in September 2022, Medunik USA introduced Pheburane oral pellets, a unique and flavor-masking formulation of sodium phenylbutyrate (NaPB) for the long-term management of certain urea cycle disorders. Pheburane, a prescription drug used in conjunction with a specific diet, offers a convenient administration method without the need for mixing. It can be consumed alone or sprinkled on food, enhancing patient compliance.

Major players in the urea cycle disorder treatment market are adopting a strategic partnership approach to advance therapies and improve disease management. In October 2021, Boehringer Ingelheim collaborated with Thoeris GmbH, an early-stage biopharmaceutical company in Europe, to explore novel therapies for patients with urea cycle disorders (UCDs). UCDs, rare diseases resulting from genetic liver dysfunctions leading to elevated ammonia levels, lack sufficient treatments. Boehringer Ingelheim's expertise in drug discovery and development aims to advance potential medications into clinical trials.

In November 2023, Zevra Therapeutics Inc. acquired Acer Therapeutics Inc. for $91 million, providing Zevra access to rare disease assets, including Edsivo and Olpruva. Edsivo is undergoing Phase III trials for vascular Ehlers-Danlos syndrome, while Olpruva has received FDA approval for certain urea cycle diseases. This acquisition enhances Zevra's market presence and diversifies its revenue stream in the rare disease therapeutics sector. Acer Therapeutics Inc. is a pharmaceutical company offering treatments for urea cycle disorders.

Major companies operating in the urea cycle disorders treatment market report are F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca Plc., Alexion Pharmaceuticals Inc., Abbott Laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceutical Co. Ltd., Danone S.A., Merck KGaA, Bausch Health Companies Inc., Grifols S.A., Horizon Therapeutics PLC, Leadiant Biosciences Inc., BioMarin Pharmaceutical Inc., Ultragenyx Pharmaceutical Inc., Travere Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Selecta Biosciences Inc., Nutricia North America, Acer Therapeutics Inc., Aeglea BioTherapeutics Inc., Synlogic Inc., Lucane Pharma SA, Recordati Rare Diseases Inc., Orpharma Pty Ltd., Mead Johnson & Company LLC

North America was the largest region in the urea cycle disorders treatment market in 2023. The regions covered in the urea cycle disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the urea cycle disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urea cycle disorders treatment market includes revenues earned by entities by hemodialysis, dietary management, and genetic counselling. The market value includes the value of related goods sold by the service provider or included within the service offering. The urea cycle disorders treatment market also includes sales of arginine, sodium phenylacetate, sodium benzoate, and carglumic acid. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urea Cycle Disorders Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urea cycle disorders treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urea cycle disorders treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urea cycle disorders treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Treatment: Amino Acid Supplements; Sodium Phenylbutyrate; Glycerol Phenylbutyrate; Sodium Benzoate; Other Treatments
2) By Enzyme Deficiency: Ornithine Transcarbamylase (OTC); Argininosuccinate Synthetase (AS); Arginase (AG); Argininosuccinate Lyase (AL); Carbamoyl Phosphate Synthase (CPS1)
3) By Route of Administration: Oral; Injectables
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned: F. Hoffmann-La Roche AG; AbbVie Inc.; Novartis AG; Sanofi S.A.; AstraZeneca Plc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13900

1. Executive Summary

2. Urea Cycle Disorders Treatment Market Characteristics

3. Urea Cycle Disorders Treatment Market Trends And Strategies

4. Urea Cycle Disorders Treatment Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Urea Cycle Disorders Treatment Market Size and Growth

5.1. Global Urea Cycle Disorders Treatment Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Urea Cycle Disorders Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Urea Cycle Disorders Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Urea Cycle Disorders Treatment Market Segmentation

6.1. Global Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Amino Acid Supplements
Sodium Phenylbutyrate
Glycerol Phenylbutyrate
Sodium Benzoate
Other Treatments
6.2. Global Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
OTC - Ornithine Transcarbamylase
AS - Argininosuccinate Synthetase (citrullinemia)
AG - Arginase
AL - Argininosuccinate Lyase
CPS1 - Carbamoyl Phosphate Synthase
6.3. Global Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Injectables
6.4. Global Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

7. Urea Cycle Disorders Treatment Market Regional And Country Analysis

7.1. Global Urea Cycle Disorders Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Urea Cycle Disorders Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Urea Cycle Disorders Treatment Market

8.1. Asia-Pacific Urea Cycle Disorders Treatment Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Urea Cycle Disorders Treatment Market

9.1. China Urea Cycle Disorders Treatment Market Overview
9.2. China Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Urea Cycle Disorders Treatment Market

10.1. India Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Urea Cycle Disorders Treatment Market

11.1. Japan Urea Cycle Disorders Treatment Market Overview
11.2. Japan Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Urea Cycle Disorders Treatment Market

12.1. Australia Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Urea Cycle Disorders Treatment Market

13.1. Indonesia Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Urea Cycle Disorders Treatment Market

14.1. South Korea Urea Cycle Disorders Treatment Market Overview
14.2. South Korea Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Urea Cycle Disorders Treatment Market

15.1. Western Europe Urea Cycle Disorders Treatment Market Overview
15.2. Western Europe Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Urea Cycle Disorders Treatment Market

16.1. UK Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Urea Cycle Disorders Treatment Market

17.1. Germany Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Urea Cycle Disorders Treatment Market

18.1. France Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Urea Cycle Disorders Treatment Market

19.1. Italy Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Urea Cycle Disorders Treatment Market

20.1. Spain Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Urea Cycle Disorders Treatment Market

21.1. Eastern Europe Urea Cycle Disorders Treatment Market Overview
21.2. Eastern Europe Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Urea Cycle Disorders Treatment Market

22.1. Russia Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Urea Cycle Disorders Treatment Market

23.1. North America Urea Cycle Disorders Treatment Market Overview
23.2. North America Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Urea Cycle Disorders Treatment Market

24.1. USA Urea Cycle Disorders Treatment Market Overview
24.2. USA Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Urea Cycle Disorders Treatment Market

25.1. Canada Urea Cycle Disorders Treatment Market Overview
25.2. Canada Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Urea Cycle Disorders Treatment Market

26.1. South America Urea Cycle Disorders Treatment Market Overview
26.2. South America Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Urea Cycle Disorders Treatment Market

27.1. Brazil Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Urea Cycle Disorders Treatment Market

28.1. Middle East Urea Cycle Disorders Treatment Market Overview
28.2. Middle East Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Urea Cycle Disorders Treatment Market

29.1. Africa Urea Cycle Disorders Treatment Market Overview
29.2. Africa Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Urea Cycle Disorders Treatment Market Competitive Landscape And Company Profiles

30.1. Urea Cycle Disorders Treatment Market Competitive Landscape
30.2. Urea Cycle Disorders Treatment Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. AbbVie Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Novartis AG
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Sanofi S.A.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. AstraZeneca Plc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Urea Cycle Disorders Treatment Market Other Major And Innovative Companies

31.1. Alexion Pharmaceuticals Inc.
31.2. Abbott Laboratories Inc.
31.3. GlaxoSmithKline Plc
31.4. Takeda Pharmaceutical Co. Ltd.
31.5. Danone S.A.
31.6. Merck KGaA
31.7. Bausch Health Companies Inc.
31.8. Grifols S.A.
31.9. Horizon Therapeutics Plc
31.10. Leadiant Biosciences Inc.
31.11. BioMarin Pharmaceutical Inc.
31.12. Ultragenyx Pharmaceutical Inc.
31.13. Travere Therapeutics Inc.
31.14. Arcturus Therapeutics Holdings Inc.
31.15. Selecta Biosciences Inc.

32. Global Urea Cycle Disorders Treatment Market Competitive Benchmarking

33. Global Urea Cycle Disorders Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Urea Cycle Disorders Treatment Market

35. Urea Cycle Disorders Treatment Market Future Outlook and Potential Analysis

35.1 Urea Cycle Disorders Treatment Market In 2028 - Countries Offering Most New Opportunities
35.2 Urea Cycle Disorders Treatment Market In 2028 - Segments Offering Most New Opportunities
35.3 Urea Cycle Disorders Treatment Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer